Cypherpunk Technologies (NASDAQ:CYPH) Given New $4.90 Price Target at Cantor Fitzgerald

Cypherpunk Technologies (NASDAQ:CYPH) had its price objective lifted by analysts at Cantor Fitzgerald from $1.60 to $4.90 in a research note issued on Thursday, Benzinga reports. The firm currently has an “overweight” rating on the stock. Cantor Fitzgerald’s price objective would indicate a potential upside of 100.00% from the company’s current price.

CYPH has been the topic of several other reports. Wall Street Zen upgraded shares of Cypherpunk Technologies from a “sell” rating to a “hold” rating in a research report on Saturday, July 4th. Weiss Ratings upgraded Cypherpunk Technologies from a “sell (e+)” rating to a “sell (d-)” rating in a report on Monday, August 17th. One equities research analyst has rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $4.90.

Cypherpunk Technologies Price Performance

Shares of CYPH opened at $2.45 on Thursday. Cypherpunk Technologies has a one year low of $0.28 and a one year high of $3.70. The company has a 50-day moving average of $1.05 and a two-hundred day moving average of $0.91. The stock has a market cap of $264.01 million, a price-to-earnings ratio of 4.38 and a beta of 0.33.

Cypherpunk Technologies (NASDAQ:CYPH) last released its quarterly earnings results on Wednesday, August 12th. The company reported $0.18 earnings per share (EPS) for the quarter.

Insider Buying and Selling

In related news, Director Thomas Dietz sold 20,000 shares of the business’s stock in a transaction that occurred on Wednesday, August 26th. The shares were sold at an average price of $1.72, for a total transaction of $34,400.00. Following the transaction, the director directly owned 132,500 shares of the company’s stock, valued at approximately $227,900. The trade was a 13.11% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Insiders own 3.50% of the company’s stock.

Institutional Investors Weigh In On Cypherpunk Technologies

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Millennium Management LLC acquired a new stake in shares of Cypherpunk Technologies during the 4th quarter valued at $37,000. LPL Financial LLC acquired a new position in shares of Cypherpunk Technologies in the fourth quarter worth $38,000. Caitong International Asset Management Co. Ltd acquired a new position in shares of Cypherpunk Technologies in the fourth quarter worth $44,000. Sequoia Financial Advisors LLC purchased a new stake in shares of Cypherpunk Technologies during the fourth quarter worth $56,000. Finally, HighTower Advisors LLC acquired a new stake in Cypherpunk Technologies during the fourth quarter valued at $59,000. Hedge funds and other institutional investors own 30.46% of the company’s stock.

About Cypherpunk Technologies

Cypherpunk Technologies Inc, previously known as Leap Therapeutics, Inc, is a company developing novel therapies for patients with cancer and implementing a digital asset treasury strategy focused on Zcash. The company’s research platform centers on modulating the tumor microenvironment to enhance anti-tumor immune responses. Cypherpunk’s proprietary pipeline includes DKN-01, a monoclonal antibody designed to neutralize Dickkopf-1 (DKK1), a protein implicated in tumor growth and immune evasion.

DKN-01 is being evaluated both as a monotherapy and in combination with checkpoint inhibitors such as pembrolizumab across multiple solid tumor indications, including gastroesophageal, pancreatic and other advanced malignancies.